ClickHouse Announces Strategic Collaboration Agreement with AWS to Advance Real-Time Data Analytics and Generative AI Innovation
10.12.2024 15:00:00 CET | Business Wire | Press release
ClickHouse, Inc., a leader in real-time analytics, announced today that it has signed a five-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to accelerate innovation in real-time data warehousing, observability, business intelligence, machine learning, and generative AI solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210976702/en/
ClickHouse announces strategic collaboration agreement with AWS (Graphic: Business Wire)
The partnership will expand on ClickHouse’s relationship with AWS and introduce new integrations between ClickHouse Cloud and AWS services including Amazon Data Firehose, Amazon Relational Database Service (RDS), AWS Glue, and Amazon Bedrock. Together, this will make it easier for customers to build and manage high-performance analytics and generative AI applications. Additionally, this will provide customers with seamless deployment, enhanced interoperability, and optimal performance of data-intensive workloads powered by ClickHouse on AWS.
In addition to tighter integrations, ClickHouse and AWS will create new tailored industry solutions for customers ranging from finance to e-commerce to gaming. These solutions will enable organizations to harness the power of ClickHouse’s real-time analytics engine alongside AWS services to drive transformational outcomes. The two companies will also work on joint go-to-market activities to empower enterprises with advanced tools to extract actionable insights from their data at scale.
“The reliable infrastructure and global reach of AWS were crucial for the successful launch of ClickHouse Cloud,” said Aaron Katz, CEO of ClickHouse. “Our AWS Marketplace listing significantly expanded our customer reach, while the AWS Partner Network helped us engage with enterprise clients. This led to 150% incremental growth in our customer base on AWS Marketplace in 2024. Now with the strategic collaboration agreement, we strengthen focus on integrations, joint solutions and go-to-market activities to help customers unlock the full potential of their data and drive innovation in their respective industries.”
“We continue to invest in helping growth-stage companies, like ClickHouse, leverage AWS infrastructure, resources, and services like AWS Marketplace to rapidly grow and scale their businesses,” said Julia Chen, Vice President AWS Partner Core. “By integrating ClickHouse Cloud with AWS services such as Amazon Bedrock, customers can leverage the strength of both companies to more easily build advanced real-time applications, such as instant fraud detection, adaptive user experiences, and dynamic operational intelligence—unlocking new possibilities to stay ahead in today’s competitive landscape.”
Helping customers get the best business value from their data lake and data analytics investments is central to the collaboration between ClickHouse and AWS. Since launching ClickHouse Cloud on AWS in 2022, thousands of ClickHouse deployments have already been created, supporting joint customers ranging from startups to Fortune 500 companies. Every day, ClickHouse customers on AWS run over 2 billion queries scanning over 1.5 quadrillion records on top of 50 petabytes of data.
"By migrating our analytics workloads to ClickHouse Cloud on AWS we simplified the integration with data residing in AWS, achieved significant improvement in query performance, and project much lower annual costs. This has let us build new features faster that help our customers better understand their consumers and how their engagement strategies are performing," said Jon Hyman, Cofounder and Chief Technology Officer at Braze [NASDAQ: BRZE].
This collaboration underscores the value of ClickHouse and AWS to provide flexibility and unlock greater business value for customers across industries. For more information please visit: www.clickhouse.com
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank, and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210976702/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom